We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

The GEM ExTra® test provides treating physicians with vital information to understand changes to a patient’s genomic profile. Knowing this information can provide a more complete biological picture of certain refractory, rare, or aggressive cancers, helping patients and physicians make informed choices when considering therapeutic treatment plans.

Primarily used by physicians, academic medical centers, and biopharma researchers, GEM ExTra (Genomic Enabled Medicine) is a comprehensive sequencing test, including both genomic (DNA) and transcriptomic (RNA) panels, and approximately 20,000 genes and 169 introns.1  


1Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7(283):283ra53. doi:10.1126/scitranslmed.aaa7161